Literature DB >> 1759543

Insulin-like growth factor II and transforming growth factor beta 1 regulate insulin-like growth factor I secretion in mouse bone cells.

F A Tremollieres1, D D Strong, D J Baylink, S Mohan.   

Abstract

Bone cells in culture produce and respond to growth factors, suggesting that local as well as systemic factors regulate bone volume. Previous studies have shown that IGF-I is the major mitogen produced by mouse bone cells and that its production is regulated by systemic agents such as PTH and estrogen. Because IGF-II and transforming growth factor beta 1 have been shown, respectively, to increase and decrease MC3T3-E1 cell proliferation, we tested the hypothesis that these two growth factors modulate the production of IGF-I in this cell line. In order to eliminate artifacts owing to IGF binding proteins, conditioned media samples were pretreated with IGF-II before measurement of IGF-I by RIA. After 24 h treatment at a density of 2.5 x 10(4) cells/cm2, IGF-II (10 micrograms/l) induced a 2.2-fold increase compared with untreated control (9.5 +/- 1.5 vs 4.2 +/- 0.44 pg/micrograms protein, p less than 0.001), whereas transforming growth factor beta 1 (1 microgram/l) caused a 66% decrease in IGF-I production (1.5 +/- 0.3 vs 4.2 +/- 0.44 pg/micrograms protein, p less than 0.001). Both IGF-II and transforming growth factor beta 1 regulated IGF-I production in a dose-, time- and cell density-dependent manner. The lowest effective doses for IGF-II and transforming growth factor beta 1 were 1 and 0.01 microgram/l, respectively. These results support a role for IGF-II and transforming growth factor beta 1 as potent modulators of IGF-I secretion in mouse bone cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759543     DOI: 10.1530/acta.0.1250538

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  6 in total

1.  Dose-dependent effects of combined IGF-I and TGF-beta1 application in a sheep cervical spine fusion model.

Authors:  F Kandziora; R Pflugmacher; M Scholz; J Schäfer; G Schollmeier; G Schmidmaier; G Duda; M Raschke; N P Haas
Journal:  Eur Spine J       Date:  2002-11-08       Impact factor: 3.134

2.  Insulin-like growth factor-II receptor expression in normal and N-methyl-N'-nitro-nitrosoguanidine exposed cell lines: assessment by flow cytometry.

Authors:  W H Thornton; L Barnett; R S MacDonald
Journal:  In Vitro Cell Dev Biol       Date:  1993-02

Review 3.  Role of insulin-like growth factor-1 in the regulation of skeletal growth.

Authors:  Subburaman Mohan; Chandrasekhar Kesavan
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

4.  Regulation of insulin-like growth factor binding protein-5, four and a half lim-2, and a disintegrin and metalloprotease-9 expression in osteoblasts.

Authors:  K E Govoni; Y G Amaar; A Kramer; E Winter; D J Baylink; S Mohan
Journal:  Growth Horm IGF Res       Date:  2005-11-28       Impact factor: 2.372

Review 5.  Skeletal effects of growth hormone and insulin-like growth factor-I therapy.

Authors:  Richard C Lindsey; Subburaman Mohan
Journal:  Mol Cell Endocrinol       Date:  2015-09-25       Impact factor: 4.102

Review 6.  Role of IGF1 and EFN-EPH signaling in skeletal metabolism.

Authors:  Richard C Lindsey; Charles H Rundle; Subburaman Mohan
Journal:  J Mol Endocrinol       Date:  2018-03-26       Impact factor: 5.098

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.